ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
17 avr. 2023 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
14 sept. 2022 08h15 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS
22 août 2022 09h00 HE
|
Oncotelic Therapeutics, Inc.
Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, AGOURA HILLS,...
Oncotelic Participating at Biotechgate Digital Partnering
17 août 2022 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited
07 avr. 2022 10h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following shareholder letter today. Dear Fellow...
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction
04 avr. 2022 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the formation of a Joint Venture (“JV”) with Dragon...
Oncotelic Presenting at BiotechGate Digital Partnering
24 févr. 2022 08h01 HE
|
Oncotelic Therapeutics, Inc.
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
07 oct. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β...
MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.
14 sept. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its...
Marina Biotech Appoints Amit Shah as Chief Financial Officer
05 oct. 2017 08h30 HE
|
Marina Biotech, Inc.
City of Industry, CA, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...